News Image

Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX.

By Mill Chart

Last update: Dec 1, 2023

Our stock screener has singled out NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as an attractive growth opportunity. NASDAQ:NBIX is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.

Exploring NASDAQ:NBIX's Growth

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:NBIX has earned a 9 for growth:

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 226.32%, which is quite impressive.
  • The Earnings Per Share has been growing by 66.75% on average over the past years. This is a very strong growth
  • NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.46%.
  • Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 55.91% on average per year.
  • Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 50.12% on average per year.
  • NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.42% yearly.

Deciphering NASDAQ:NBIX's Valuation Rating

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:NBIX has achieved a 6 out of 10:

  • Based on the Price/Earnings ratio, NBIX is valued cheaply inside the industry as 94.15% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 95.82% of the companies listed in the same industry.
  • 94.48% of the companies in the same industry are more expensive than NBIX, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 95.65% of the companies listed in the same industry.
  • The excellent profitability rating of NBIX may justify a higher PE ratio.
  • A more expensive valuation may be justified as NBIX's earnings are expected to grow with 65.62% in the coming years.

ChartMill's Evaluation of Health

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 7 out of 10:

  • NBIX has an Altman-Z score of 9.41. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • NBIX has a better Altman-Z score (9.41) than 88.80% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 2.39 indicates that NBIX has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.34 indicates that NBIX has no problem at all paying its short term obligations.

Profitability Analysis for NASDAQ:NBIX

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 8 out of 10:

  • NBIX has a better Return On Assets (6.71%) than 96.49% of its industry peers.
  • NBIX has a Return On Equity of 9.54%. This is amongst the best in the industry. NBIX outperforms 95.65% of its industry peers.
  • NBIX's Return On Invested Capital of 12.95% is amongst the best of the industry. NBIX outperforms 96.99% of its industry peers.
  • The last Return On Invested Capital (12.95%) for NBIX is above the 3 year average (12.37%), which is a sign of increasing profitability.
  • Looking at the Profit Margin, with a value of 10.71%, NBIX belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NBIX has grown nicely.
  • NBIX has a Operating Margin of 19.50%. This is amongst the best in the industry. NBIX outperforms 96.66% of its industry peers.
  • NBIX has a better Gross Margin (97.82%) than 97.32% of its industry peers.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Our latest full fundamental report of NBIX contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (2/21/2024, 12:42:03 PM)

130.4

-2.25 (-1.7%)

NBIX News

News Image5 days ago - Investor's Business DailyBeam Therapeutics Stock Shows Healthy Relative Strength Improvement

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

News Image6 days ago - Investor's Business DailyAlkermes Stock Gets RS Rating Upgrade; Profits Surge

In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.

News Image8 days ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image12 days ago - Investor's Business DailyAmicus Therapeutics Stock Sees Improved Relative Strength Rating

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

News Image13 days ago - Investor's Business DailyStock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.

News Image14 days ago - Seeking AlphaNeurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M (NASDAQ:NBIX)

Neurocrine Biosciences reports Q4 earnings, beating EPS expectations but missing revenue estimates.

News Image14 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2023...

News Image14 days ago - ChartmillExploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

News Image15 days ago - ChartmillNASDAQ:NBIX is not too expensive for the growth it is showing.

While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable.

News Imagea month ago - Market News VideoInteresting NBIX Put And Call Options For March 15th
News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results...

News Image2 months ago - Investor's Business DailyEli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

NBIX Links
Follow us for more